MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 529909 | Name: FP-21399 (Sodium)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FP-21399 is an HIV fusion inhibitor potentially for the treatment of HIV infection

Chemical Structure

FP-21399 (Sodium)
FP-21399 (Sodium)
CAS#170020-61-8

Theoretical Analysis

MedKoo Cat#: 529909

Name: FP-21399 (Sodium)

CAS#: 170020-61-8

Chemical Formula: C40H20Cl4N6Na4O16S4

Exact Mass:

Molecular Weight: 1202.63

Elemental Analysis: C, 39.95; H, 1.68; Cl, 11.79; N, 6.99; Na, 7.65; O, 21.29; S, 10.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
761377-68-8 (FP-21399 Free base)
Synonym
FP-21399; FP21399; FP 21399
IUPAC/Chemical Name
sodium 5-(2,3-dichlorobenzamido)-3-((E)-(4-((E)-(8-(2,4-dichlorobenzamido)-1-hydroxy-3,6-disulfonatonaphthalen-2-yl)diazenyl)phenyl)diazenyl)-4-hydroxynaphthalene-2,7-disulfonate
InChi Key
MSFYKYHLEKUTHF-ZXKDDXFLSA-J
InChi Code
InChI=1S/C40H24Cl4N6O16S4.4Na/c41-19-4-9-24(27(43)14-19)39(53)45-28-15-22(67(55,56)57)10-17-12-30(69(61,62)63)35(37(51)32(17)28)49-47-20-5-7-21(8-6-20)48-50-36-31(70(64,65)66)13-18-11-23(68(58,59)60)16-29(33(18)38(36)52)46-40(54)25-2-1-3-26(42)34(25)44;;;;/h1-16,51-52H,(H,45,53)(H,46,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66);;;;/q;4*+1/p-4/b49-47+,50-48+;;;;
SMILES Code
O=S(C1=C(/N=N/C2=CC=C(/N=N/C3=C(S(=O)([O-])=O)C=C4C=C(S(=O)([O-])=O)C=C(NC(C5=CC=C(Cl)C=C5Cl)=O)C4=C3O)C=C2)C(O)=C6C(NC(C7=CC=CC(Cl)=C7Cl)=O)=CC(S(=O)([O-])=O)=CC6=C1)([O-])=O.[Na+].[Na+].[Na+].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 761377-68-8(FP-21399 Free base) 170020-61-8(FP-21399 Sodium)

Preparing Stock Solutions

The following data is based on the product molecular weight 1,202.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Poli G, Vicenzi E. FP-21399 (Lexigen Pharmaceuticals). IDrugs. 2001 Nov;4(11):1293-5. PubMed PMID: 15942835. 2: Yamaguchi N, Dahl T, Ono M, Gillies S. Liquid chromatographic determination of FP-21399 in plasma of patients with HIV infection. J Pharm Biomed Anal. 2000 Sep;23(4):715-22. PubMed PMID: 10975247. 3: Dezube BJ, Dahl TA, Wong TK, Chapman B, Ono M, Yamaguchi N, Gillies SD, Chen LB, Crumpacker CS. A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study. J Infect Dis. 2000 Aug;182(2):607-10. PubMed PMID: 10915097. 4: Zhang JL, Choe H, Dezube BJ, Farzan M, Sharma PL, Zhou XC, Chen LB, Ono M, Gillies S, Wu Y, Sodroski JG, Crumpacker CS. The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry. Virology. 1998 May 10;244(2):530-41. PubMed PMID: 9601521. 5: Ono M, Wada Y, Wu Y, Nemori R, Jinbo Y, Wang H, Lo KM, Yamaguchi N, Brunkhorst B, Otomo H, Wesolowski J, Way JC, Itoh I, Gillies S, Chen LB. FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes. Nat Biotechnol. 1997 Apr;15(4):343-8. PubMed PMID: 9094135. 6: FP 21399. Drugs R D. 1999 Nov;2(5):343-4. PubMed PMID: 10728476. 7: Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. An update in the development of HIV entry inhibitors. Curr Top Med Chem. 2007;7(13):1273-89. Review. PubMed PMID: 17627557. 8: Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des. 2005;11(14):1805-43. Review. PubMed PMID: 15892677. 9: Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. New advances in HIV entry inhibitors development. Curr Drug Targets Infect Disord. 2004 Dec;4(4):339-55. Review. PubMed PMID: 15578975. 10: Cadman J. Looking down the drug pipeline. GMHC Treat Issues. 1998 Mar;12(3):5-9. PubMed PMID: 11365393. 11: Protease inhibitors and beyond. PI Perspect. 1997 Mar;(No 21):15-6. PubMed PMID: 11364210.